Abstract:BACKGROUND:Human leukocyte antigen G (HLA-G) is a non-classical major histocompatibility complex class I molecule that has multiple immune regulatory functions including the induction of immune tolerance. The detection of HLA-G expression might serve as a clinical marker in the prediction of clinical outcomes for certain types of carcinoma. Currently, we investigated whether or not HLA-G is also expressed in patients with hepatocellular carcinoma (HCC), and whether the expression has clinical value.METHODS:Serum levels of secreted HLA-G (sHLA-G) were measured by ELISA in 36 patients with HCC, 25 patients with liver cirrhosis (LC) and 25 healthy individuals. The expression of HLA-G in liver tissue was further studied using Western blotting in 36 patients with HCC and 25 with LC. The correlations between HLA-G status and various clinicopathological parameters including survival were analyzed.RESULTS:The ELISA assay showed that the serum levels of sHLA-G in the HCC, LC and healthy groups were 132.6+/-31.4, 63.5+/-22.1, and 47.0+/-15.5 U/ml, respectively. Analysis of variance was used for inter-group comparison and differences were found between the HCC group and the other two groups (both P<0.01), while no difference was found between the LC group and the healthy group (P=0.112). HLA-G protein expression in liver tissue was found in 66.7% (24/36) of the primary sites of HCC, but not in benign lesions (LC). Further, the HLA-G expression in tumors had no significant correlation with the parameters of age, gender, histological grade and alpha-fetoprotein level. However, patients with HLA-G-positive tumors had a shorter postoperative survival time than those with HLA-G-negative tumors (P=0.014). Also, univariate analysis showed that HLA-G was an independent prognostic factor.CONCLUSION:Our results indicated that the expression of HLA-G was a characteristic feature of HCC and patients with positive expression of HLA-G in malignant liver tissue had a poor prognosis.

Expression of Hepatocytic Antigen in Gastric Carcinoma and Its Clinical Significance

Expression and clinical significance of GS,E-cadherin and β-catenin in hepatocellular carcinoma

HGC - 1 expression in gastric carcinoma and its relationship with clinicopathological fac-tors and prognosis

[Expression and Clinical Significance of Hepatocellular Cancer Antigen Genes in Human Hepatocellular Carcinoma].

[The Expression of Hepatitis C Antigen in Hepatitis and Liver Cancer Tissues].

Expression of Cyclin A in Hepatocellular Carcinoma and Its Clinical Signific Ance

The Expression and Significance of CA15 -3 in Gastric Carcinoma

Expression of HGF in gastric carcinoma and the correlation with lymphangiogenesis and lymph node metastasis

Expression of HLA-G in Patients with Hepatocellular Carcinoma.

Expression of CK20 and PCNA in Gastric Carcinoma and Its Clinical Significance

Expression of Cdx2 and Hepatocyte Antigen in Gastric Carcinoma: Correlation with Histologic Type and Implications for Prognosis

Expression of HAb18G/CD147 in large sample of gastric cancer tissue specimen

Expression and Clinical Significance of CD8 + T Cells in Gastric Carcinoma Tissues

Expression and Clinical Significance of Adhesion Molecule CD11c in Gastric Carcinoma

Expression of P53, EGFR, HER-2, VEGF in Gastric Carcinoma and Its Relation with the Prognosis of Gastric Carcinoma Patients

Expression of hypoxia inducible factor-1α and vascular endothelial growth factor in gastric cancer tissues and its relationship with tumor cell proliferation

Expressions of CD34 and CD117 in Human Hepatocellular Carcinomas and the Clinical Significance

Expression of the protein and gene of AR in gastric cancer clinical significance

Expression of P53 and PCNA in gastric carcinoma detected by tissue microarray

Expressions of PCNA and Cyt C Protein in Gastric Carcinoma Tissue and Their Clinical Significances

Expression of Glut1 and HIF-1α in Human Hepatocellular Carcinoma and Its Clinical Significance